On November 17, 2022, Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, launched with $78 million from a Series A financing. The Series A financing was led by SR One, a16z Bio + Health, and Norwest Venture Partners, and also included SV Angel, Liquid 2 Ventures, and Hawktail.

Rezo’s Sequence to Systems to Drugs (SSD) platform integrates data from proteomics, genetics, structural biology, and chemical biology approaches using sophisticated computational methods to create comprehensive maps of molecular disease networks. The platform enables the rapid identification and study of disease-causing protein and genetic interactions, which would be difficult to discover using traditional, often siloed, scientific methods. Rezo’s disease-specific maps are designed to pinpoint novel, druggable targets that can be attacked with a range of treatment modalities. 

Wilson Sonsini represented lead investors SR One and Norwest in the transaction. The team includes:

Corporate
Dan Koeppen
Meg Burton
Bridget Balisy

Intellectual Property
Mike Hostetler
Eric Grote
Brandon Tavshanjian

Technology Transactions - Biotech
Miranda Biven
Sarah Siedlak

For more information, please see Rezo's press release.